156 related articles for article (PubMed ID: 15917704)
21. Sequential chemoimmunotherapy for metastatic melanoma.
Richards JM
Semin Oncol; 1991 Oct; 18(5 Suppl 7):91-5. PubMed ID: 1948135
[TBL] [Abstract][Full Text] [Related]
22. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
24. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
26. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
Bajetta E; Del Vecchio M; Nova P; Fusi A; Daponte A; Sertoli MR; Queirolo P; Taveggia P; Bernengo MG; Legha SS; Formisano B; Cascinelli N
Ann Oncol; 2006 Apr; 17(4):571-7. PubMed ID: 16469753
[TBL] [Abstract][Full Text] [Related]
29. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
[TBL] [Abstract][Full Text] [Related]
30. A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Ron IG; Sarid D; Ryvo L; Sapir EE; Schneebaum S; Metser U; Asna N; Inbar MJ; Safra T
Melanoma Res; 2006 Feb; 16(1):65-9. PubMed ID: 16432458
[TBL] [Abstract][Full Text] [Related]
31. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
33. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
[TBL] [Abstract][Full Text] [Related]
34. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Thompson JA; Gold PJ; Fefer A
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
[TBL] [Abstract][Full Text] [Related]
35. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
36. A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Ready N; Aronson F; Wanebo H; Kennedy T
Am J Clin Oncol; 2005 Oct; 28(5):479-84. PubMed ID: 16199988
[TBL] [Abstract][Full Text] [Related]
37. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
[TBL] [Abstract][Full Text] [Related]
38. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma.
Luikart SD; Kennealey GT; Kirkwood JM
J Clin Oncol; 1984 Mar; 2(3):164-8. PubMed ID: 6199481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]